Travere Therapeutics (RTRX) Stock Price, News & Analysis

Company Overview

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Key Stats

• Today's Range: $31.43 to $33.08
• 50-Day Range: $24.25 to $28.18
• 52-Week Range: $8.98 to $24.96
• Volume: 1.20 million shs
• Average Volume: 412,277 shs
• Market Capitalization: $1.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/05/2020
• Today: 9/04/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RTRX
• CIK: 1438533
• Web: www.retrophin.com
• Phone: (888) 969-7879
• Fax: N/A
• Employees: 221
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$146.43 million
• Net Margins: -49.13%
• Pretax Margin: N/A
• Return on Equity: -36.38%
• Return on Assets: -14.90%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 7.23
• Quick Ratio: 7.14

Sales & Book Value

• Annual Sales: $175.34 million
• Price / Sales: 9.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.15 per share
• Price / Book: 6.15

Miscellaneous

• Outstanding Shares: 51,052,000
• Free Float: N/A
• Market Cap: $1.62 billion
• Optionable: Not Optionable
• Beta: 0.67